CA2288876A1 - Systeme d'administration de medicaments - Google Patents

Systeme d'administration de medicaments Download PDF

Info

Publication number
CA2288876A1
CA2288876A1 CA002288876A CA2288876A CA2288876A1 CA 2288876 A1 CA2288876 A1 CA 2288876A1 CA 002288876 A CA002288876 A CA 002288876A CA 2288876 A CA2288876 A CA 2288876A CA 2288876 A1 CA2288876 A1 CA 2288876A1
Authority
CA
Canada
Prior art keywords
drug delivery
microspheres
delivery composition
poly
chemosensitizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002288876A
Other languages
English (en)
Inventor
Xiao Yu Wu
Zhi Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2288876A1 publication Critical patent/CA2288876A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Abstract

Composition permettant d'administrer des médicaments, qui comprend des microsphères contenant au moins un agent chimiothérapique et au moins un agent chimiosensibilisant, et dans laquelle les microsphères comportent une matrice polymère biodégradable renfermant des groupes fonctionnels qui s'associent à l'agent chimiothérapique et à l'agent chimiosensibilisant.
CA002288876A 1997-05-06 1998-05-06 Systeme d'administration de medicaments Abandoned CA2288876A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4571097P 1997-05-06 1997-05-06
US60/045,710 1997-05-06
PCT/CA1998/000419 WO1998050018A1 (fr) 1997-05-06 1998-05-06 Systeme d'administration de medicaments

Publications (1)

Publication Number Publication Date
CA2288876A1 true CA2288876A1 (fr) 1998-11-12

Family

ID=21939455

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002288876A Abandoned CA2288876A1 (fr) 1997-05-06 1998-05-06 Systeme d'administration de medicaments

Country Status (3)

Country Link
AU (1) AU7201998A (fr)
CA (1) CA2288876A1 (fr)
WO (1) WO1998050018A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1312110B1 (it) * 1999-05-18 2002-04-04 Istituto Biochimico Pavese Pha Addotti antibiotico-polimero polisaccaridico naturale
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
ES2376739T3 (es) * 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
US20060216341A1 (en) * 2003-04-02 2006-09-28 Paul Tardi Compositions for treating drug resistance
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
PL1811979T3 (pl) * 2004-09-27 2009-04-30 Sigmoid Pharma Ltd Mikrokapsułki zawierające metyloksantynę i kortykosteroid
EP2380564B1 (fr) 2007-04-04 2014-10-22 Sigmoid Pharma Limited Composition pharmaceutique orale
EP2061587A1 (fr) 2007-04-26 2009-05-27 Sigmoid Pharma Limited Fabrication de minicapsules multiples
GB2483815B (en) 2009-05-18 2013-12-25 Sigmoid Pharma Ltd Composition comprising oil drops
EP2464341B1 (fr) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Compositions immunomodulatrices comprenant une matrice polymère et une phase huileuse
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2941694A1 (fr) 2014-03-06 2015-09-11 Research Institute At Nationwide Children's Hospital Preparations probiotiques et methodes d'utilisation associees
PT3215127T (pt) 2014-11-07 2021-02-10 Sublimity Therapeutics Ltd Composições que compreendem ciclosporina
US20180207067A1 (en) * 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
WO2017066719A2 (fr) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Agents spécifiques interférant avec hu
IT201700108526A1 (it) * 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2565102B1 (fr) * 1984-06-05 1987-03-20 Paris Sud Universite Microcapsules biodegradables a base de serumalbumine, leur preparation et leur application a la liberation in situ de medicuments
DE3635930A1 (de) * 1986-10-22 1988-04-28 Basf Ag Wirkstoffe zur anwendung bei der behandlung von tumoren
US5484584A (en) * 1990-10-02 1996-01-16 Board Of Regents, The University Of Texas System Therapeutic and diagnostic use of modified polymeric microcapsules
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
GB9517883D0 (en) * 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition

Also Published As

Publication number Publication date
WO1998050018A1 (fr) 1998-11-12
AU7201998A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
CA2288876A1 (fr) Systeme d'administration de medicaments
Narayanaswamy et al. Hydrogels and their applications in targeted drug delivery
US7186413B2 (en) Hydrogels and water soluble polymeric carriers for drug delivery
Tian et al. Hyaluronic acid hydrogel as Nogo-66 receptor antibody delivery system for the repairing of injured rat brain: in vitro
Yadav et al. An insight on hyaluronic acid in drug targeting and drug delivery
Yadav et al. Development and characterization of hyaluronic acid–anchored PLGA nanoparticulate carriers of doxorubicin
CN101267840B (zh) 通过间接化学轭合获得的透明质酸或其衍生物的抗肿瘤生物轭合物
Jain et al. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors
JP4619457B2 (ja) 徐放性製剤
JP2002526383A (ja) 薬物分子と生分解性高分子の共有結合を用いた薬物分子伝達システム
US20070275991A1 (en) Drug Delivery From Embolic Agents
CN115038465A (zh) 炎症反应性抗炎水凝胶
JP2005517048A (ja) シクロデキストリングラフト生体適合性両親媒性ポリマーおよびその製造および使用方法
Esfandyari-Manesh et al. S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles containing Imatinib for targeting drug delivery to atherosclerotic plaques
EP1835888B1 (fr) Complexe acide cholanique-chitosane formant automatiquement des agregats et son procede de preparation
EP1383539B1 (fr) Complexe de chitosane-substance anticancereuse formant automatiquement des corps par agregation et son procede de preparation
Bachkar et al. Nanosponges: A potential nanocarrier for targeted drug delivery
Liu et al. Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance
Zheng et al. Preparation, characterization, and tissue distribution in mice of lactosaminated carboxymethyl chitosan nanoparticles
JP2003504312A (ja) 生物学的に活性な材料
Campisi et al. ONCOFID™-P a hyaluronic acid paclitaxel conjugate for the treatment of refractory bladder cancer and peritoneal carcinosis
Yuan et al. Surface multi-functionalization of poly (lactic acid) nanoparticles and C6 glioma cell targeting in vivo
Cho et al. Mucoadhesive hybrid gel improves intraperitoneal platinum delivery
WO2007132205A2 (fr) Vecteur pharmaceutique nanoparticulaire
CN111686075A (zh) 一种以纳米胶束为交联剂的原位水凝胶组合物及其应用

Legal Events

Date Code Title Description
FZDE Dead